Glenmark Pharmaceuticals Limited has actually revealed the introduction of Favipiravir under the brand name FabiFlu in tablet type for the treatment of moderate & moderate coronavirus( COVID-19) cases in India.
Almost 80%of all COVID-19 favorable cases in India are under this category. FabiFlu is India’s very first oral antiviral drug for treatment of mild & moderate COVID-19 clients, the business stated.
Glenmark’s antiviral drug Fabiflu to be used for clients with moderate and moderate symptoms
” It is a significant step in the fight against COVID-19 India. Glenmark is leading the flight. We are not looking it as a company chance. The priority is to make the drug available to as lots of clients and save lives,” stated Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals Limited in a video conference.
ICMR advises use of faster COVID-19 screening set
The company had on Friday got approval from Indian drug regulator for manufacturing and marketing of Favipiravir in oral kind in India.
On Saturday the company said the drug would be available from the evening near its factory locations and pan India in 7 to 10 days.
The drug will be available in strips consisting of 34 tables priced at 3,500 which works out to be103 per tablet.
The prescribed dose is 18 tablets on the first day with 9 tablets of 200 mg each in early morning and evening. From second day onwa